Model for the three-dimensional structure of vitronectin: Predictions for the multi-domain protein from threading and docking

Proteins: Structure, Function and Genetics

Volumn 44, Issue 3, 2001, Pages 312-320

  Xu, Dong ^a,c   Baburaj, Kunnumal ^b,c   Peterson, Cynthia B ^b,c   Xu, Ying ^a,c  

^a OAK RIDGE NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c Life Sciences Division ^*  (United States)

Author keywords

Docking; Domains; Heparin; Protein structure prediction; Threading; Vitronectin

Indexed keywords

HEPARIN; SOMATOMEDIN B; VITRONECTIN;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; DISULFIDE BOND; LIGAND BINDING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN STRUCTURE;

AMINO ACID SEQUENCE; COMPUTATIONAL BIOLOGY; DISULFIDES; HEPARIN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; SOMATOMEDINS; SULFHYDRYL COMPOUNDS; VITRONECTIN;

EID: 0035882558     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/prot.1096     Document Type: Article

References (62)

1. Structure and biological role of vitronectin
2. Vitronectin
3. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs
4. Site-directed mutagenesis of the arginine-glycine-aspartic acid in vitronectin abolishes cell adhesion
5. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin
6. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin
7. The use of fluorescent probes to characterize conformational changes in the interaction between vitronectin and plasminogen activator inhibitor-1
8. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor
9. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
10. Multiple interactions between human vitronectin and Staphylococcus aureus
11. The hemopexin-type repeats of human vitronectin are recognized by Streptococcus pyogenes
12. Identification of novel heparin-binding domains of vitronectin
13. Prediction of protein secondary structure at better than 70% accuracy
14. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation
15. The cluster of basic amino acids in vitronectin contributes to its binding of plasminogen activator inhibitor-1: Evidence from thrombin-, elastase- and plasmin-cleaved vitronectins and antipeptide antibodies
16. Domain structure of vitronectin. Alignment of active sites
17. Activation of the collagen-binding of endogenous serum vitronectin by heating, urea and glycosaminoglycans
18. Two collagen-binding domains of vitronectin
19. Specific binding of plasminogen to vitronectin. Evidence for a modulatory role of vitronectin on fibrin(ogen)-induced plasmin formation by tissue plasminogen activator
20. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8 and C9 and perforin from cytolytic T-cells and inhibits their lytic activities
21. Vitronectin-mediated inhibition of complement: Evidence for different binding sites for C5b-7 and C9
22. Structural requirements for the extracellular interaction of plasminogen activator inhibitor-1 with endothelial cell matrix-associated vitronectin
23. Endogenous cleavage of the Arg-379-Ala-380 bond in vitronectin results in a distinct conformational change which buries Ser-378, its site of phosphorylation by protein kinase A
24. Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin. Use in mapping the PAI-1 binding site
25. A domain structure common to hemopexin, vitronectin, interstitial collagenase, and a collagenase homolog
26. Characterization of the denaturation and renaturation of human plasma vitronectin. I. Biophysical characterization of protein unfolding and multimerization
27. Characterization of the denaturation and renaturation of human plasma vitronectin. II. Investigation into the mechanism of formation of multimers
28. Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein
29. Alteration of vitronectin. Characterization of changes induced by treatment with urea
30. Two functionally distinct pools of vitronectin (Vn) in the blood circulation: Identification of a heparin-binding competent population of Vn within platelet alpha-granules
31. An efficient computational method for globally optimal threading
32. Protein threading using PROSPECT: Design and evaluation
33. Protein structure prediction issue
34. Protein threading by PROSPECT: A prediction experiment in CASP3
35. Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group
36. Mapping the protein universe
37. Dictionary of recurrent domains in protein structures
38. Comparative protein modelling by satisfaction of spatial restraints
39. Low-resolution docking: Prediction of complexes for underdetermined structures
40. N.M.R. and molecular-modelling studies of the solution conformation of heparin
41. VMD: Visual molecular dynamics
42. Arrangement of disulfide bridges and positions of sulfhydryl groups in tetanus toxin
43. Sequence location of a putative transglutaminase cross-linking site in human vitronectin
44. Saturated BLAST: An automated multiple intermediate sequence search used to detect distant homology
45. GenTHREADER: An efficient and reliable protein fold recognition method for genomic sequences
46. ModBase: A database of annotated comparative protein structure models
47. Orientation of heparin-binding sites in native vitronectin. Analyses of ligand binding to the primary glycosaminoglycan-binding site indicate that putative secondary sites are not functional
48. WHAT IF: A molecular modeling and drug design program
49. PRO-CHECK: A program to check the stereochemical quality of protein structures
50. Structural analysis based on state-space modeling
51. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin
52. Native and multimeric vitronectin exhibit similar affinity for heparin. Differences in heparin binding properties induced upon denaturation are due to self association into a multivalent form
53. The presence of methionine or threonine at position 381 in vitronectin is correlated with proteolytic cleavage at Arginine 379
54. Neutralization and binding of heparin by S protein/vitronectin in the inhibition of Factor Xa by antithrombin. Involvement of an inducible heparin-binding domain of S-protein/vitronectin
55. Characterization of the ligand binding activities of vitronectin: Interaction of vitronectin with lipids and identification of the binding domains for various ligands using recombinant domains
56. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor
57. Evidence for a specific interaction of vitronectin with arginine: Effects of reducing agents on the expression of functional domains and immunoepitopes
58. Tachylectin 2: Crystal structure of a specific GlcNAc/GalNAc-binding lectin involved in the innate immunity host defense of the Japanese horseshoe crab Tachypleus tridentatus
59. Structural basis of activity and subunit recognition in G protein heterotrimers
60. Full length and truncated forms of vitronectin provide insight into effects of proteolytic processing on function
61. β propellers: Structural rigidity and functional diversity
62. An extracellular β-propeller predicted in lipoprotein and scavenger receptors, tyrosine kinases, epidermal growth factor precursor, and extracellular matrix components